Is this your brand? Sign in to claim ownership.

Sign in to claim this brand

Biogenex Laboratories, Inc.

US

Last updated May 23, 2026

What Biogenex Laboratories, Inc. makes

Biogenex Laboratories, Inc. manufactures in vitro diagnostic (IVD) antibodies targeting specific cellular and tissue markers, including cytokeratin, Ki67, progesterone receptor, synaptophysin, chromogranin A, CD45, and CD31. Their portfolio also includes antibodies for melanoma-associated antigens (e.g., MELAN-A, MUM1/IRF4) and viral markers (e.g., adenovirus). Additionally, the company produces automated microscope slide staining systems for immunohistochemistry applications.

The company’s products are classified under FDA’s In Vitro Diagnostic Device regulations, with devices falling into Class I and Class II categories. These antibodies and staining systems are listed in the FDA’s Unique Device Identifier (UDI) database. Biogenex Laboratories, Inc. is based in the United States.

Written from this company's registered devices by an AI model, and not verified by a human reviewer.

Frequently asked questions

What types of medical devices does Biogenex Laboratories, Inc. manufacture?

Biogenex Laboratories, Inc. specializes in in vitro diagnostic (IVD) devices, primarily antibodies designed for immunohistochemistry. These antibodies target specific cellular and tissue markers such as cytokeratin, Ki67, progesterone receptors, synaptophysin, chromogranin A, CD45, CD31, and melanoma-associated antigens like MELAN-A and MUM1/IRF4. The company also produces automated microscope slide staining systems, which assist in the visualization of these markers for diagnostic purposes.

Where is Biogenex Laboratories, Inc. based?

Biogenex Laboratories, Inc. is headquartered in the United States. The company’s location is relevant for regulatory compliance and distribution, as its devices are designed and manufactured under U.S. regulatory oversight.

Which regulatory registries list Biogenex Laboratories, Inc.’s devices?

Biogenex Laboratories, Inc.’s devices are included in the FDA’s Unique Device Identifier (UDI) database. This registry helps track and identify medical devices authorized for use in the U.S., ensuring transparency and traceability for healthcare providers and regulators.

How are Biogenex Laboratories, Inc.’s devices classified under FDA regulations?

Biogenex’s devices fall under the FDA’s In Vitro Diagnostic Device regulations and are classified as either Class I or Class II. Class I devices generally pose minimal risk and require less regulatory scrutiny, while Class II devices involve moderate risk and may require specific controls to ensure safety and effectiveness. Classification depends on factors like the device’s intended use and potential health impact.

AI-generated from registry data and not verified by a human reviewer.

Information

Country
US
Address
—
Website
—
LinkedIn
—
Facebook
—
Email
—
Phone
—
PRRC Contact
—
EUDAMED SRN
—
FDA FEI Number
—
DUNS Number
—

Catalogue (756)

Page 8 of 16
DeviceModel / ReferenceRegistriesClassStatus
Anti-Ema AM182-5M
FDA UDI
Class IActive
Super Sensitive Wash Buffer HK583-5K
FDA UDI
Class IActive
Anti-Bcl-2 AN723-5M
FDA UDI
Class IActive
Anti-PR (Insite) MU328-UC
FDA UDI
Class IIActive
Anti-Hsv I AR084-5R
FDA UDI
Class IActive
Anti- FLI-1 AMB24-5M
FDA UDI
Class IActive
Anti- Estrogen Receptor-Alpha NU710-5UC
FDA UDI
Class IActive
Anti-Vimentin AM074-10M
FDA UDI
Class IActive
Anti-Beta-Hcg MU395-UC
FDA UDI
Class IActive
Anti-Cytokeratin 7 AM255-10M
FDA UDI
Class IActive
Anti-Gfap AM020-5M
FDA UDI
Class IActive
Anti-Msh6 MU999-UC
FDA UDI
Class IActive
Anti-Myosin AM109-5M
FDA UDI
Class IActive
Anti-OCT-3/4 AMB84-5M
FDA UDI
Class IActive
Anti-Insulin AM029-5M
FDA UDI
Class IActive
Anti-Luteinizing Hormone AN787-5M
FDA UDI
Class IActive
Anti-Inhibin Alpha AM446-5M
FDA UDI
Class IActive
Pipette Tips (Blue) XT153-10X
FDA UDI
Class IActive
Anti-ER (Insite) MU368-5UC
FDA UDI
Class IIActive
P27 (kip1) AY817-YCD
FDA UDI
Class IActive
Anti-Her2/Erbb2 AN726-10M
FDA UDI
Class IActive
Anti- Cytokeratin Hmw AM133-5M
FDA UDI
Class IActive
Anti-Cd20 MU537-UC
FDA UDI
Class IActive
Cd56 (natural Killer Cell, Ncam) AM268-10M
FDA UDI
Class IActive
Anti-Cd43 MU305-UC
FDA UDI
Class IActive
Anti-Cd34 MU236-5UC
FDA UDI
Class IActive
Anti-SOX10 AM995-10M
FDA UDI
Class IActive
Anti-Egfr AN781-5M
FDA UDI
Class IActive
Anti-Cd68 MU549-UC
FDA UDI
Class IActive
Anti-Pdl-1 AN921-5M
FDA UDI
Class IActive
Anti-Estrogen Receptor-Alpha NU710-UC
FDA UDI
Class IIActive
Anti-Oct-2 NU830-UC
FDA UDI
Class IActive
Anti-Myosin Heavy Chain MU331-UC
FDA UDI
Class IActive
Anti- Oct-4 NU724-UC
FDA UDI
Class IActive
Anti-Cytokeratin 8 AM142-5M
FDA UDI
Class IActive
Anti-P504s AN449-5M
FDA UDI
Class IActive
Anti-Cytokeratin 5 AN847-5M
FDA UDI
Class IActive
Anti-Cd66 AM325-5M
FDA UDI
Class IActive
Anti-Vegf AR483-5R
FDA UDI
Class IActive
Anti-Human Progesterone Receptor AN711-10M
FDA UDI
Class IActive
Anti-Nse MU055-UC
FDA UDI
Class IActive
Anti-ER (Insite) AM368-10M
FDA UDI
Class IIActive
Pipette Tips XT145-05X
FDA UDI
Class IActive
Anti- IDH1 AMA22-5M
FDA UDI
Class IActive
Anti-P53 Protein AM239-10M
FDA UDI
Class IActive
Anti-Fascin AM488-5M
FDA UDI
Class IActive
Anti-Laminin PU078-UP
FDA UDI
Class IActive
Anti-C-Erbb-2 (her-2/Neu) AM134-5M
FDA UDI
Class IActive
Anti-Cytomegalovirus (CMV) MU997-UC
FDA UDI
Class IActive
Anti-Hla-Dr MU154-UC
FDA UDI
Class IActive

Related Companies

Authorised Representatives

No authorised representatives on record.

Importers

Not available yet.

Notified Bodies

Not available yet.

Authorities

Not available yet.

FDA Recalls (11)

Recalls reported by this firm to the FDA. Listed at company level — FDA recall records don't identify a specific catalogue device.

Biogenex Laboratories, Inc. has 11 recall records initiated between February 9, 2006, and July 1, 2014, all of which are recorded as terminated. The reasons cited include potential product system failures that could cause operator exposure to Hemo-De solution, distribution without 510(k) approval, misbranding and mislabeling issues related to non-compliance with Analyte Specific Reagent (ASR) requirements, incorrect labeling of reagent contents and antibody cocktails, and a defective bulk reagent dispensing mechanism that could result in spills.

AI-generated summary of the recall records listed below. It describes what the records state and is not an assessment of this manufacturer.

DateRecall No.ClassStatusReason
Jul 1, 2014Z-2113-2014—terminated

Product was distributed without 510(k) approval.

Jan 23, 2009Z-1016-2010—terminated

Under certain conditions, product system failure has the potential to cause operator injury due to splash of Hemo-De solution.

Jan 24, 2008Z-1471-2008—terminated

Bulk reagent dispensing mechanism may break resulting in reagent spill and possible exposure to chemicals.

Oct 3, 2006Z-0217-2007—terminated

Mislabeling: The product's "contents section " labeling (outer box) is mislabeled incorrectly printed as '1 x 100 mL Alk Phos Label' which should read '1 x 100 mL HRP Label'. A second, smaller label, incorrectly reads "RTU MultiLink HPR/AEC" which should be labeled as "RTU MultiLink HPR". The reagent vials in the box are correctly labeled.

Sep 5, 2006Z-1519-06—terminated

Mislabeling: Anti-CD45 cocktail antibody mislabeled as Ki-67.

Jun 2, 2006Z-1439-06—terminated

Misbranding-The product labeling (label and insert) is misbranded in that the product does not comply with the labeling requirements for an Analyte Specific

Jun 2, 2006Z-1438-06—terminated

Misbranding-The product labeling (label and insert) is misbranded in that the product does not comply with the labeling requirements for an Analyte Specific Reagent (ASR).

Feb 9, 2006Z-0608-06—terminated

Products produce granular staining in immunostained tissue sections, which may lead to misdiagnosis due to false positive result.

Feb 9, 2006Z-0609-06—terminated

Products produce granular staining in immunostained tissue sections, which may lead to misdiagnosis due to false positive result.

Feb 9, 2006Z-0606-06—terminated

Products produce granular staining in immunostained tissue sections, which may lead to misdiagnosis due to false positive result.

Feb 9, 2006Z-0607-06—terminated

Products produce granular staining in immunostained tissue sections, which may lead to misdiagnosis due to false positive result.